← boardnext 2026-07-30next 2026-09-22next 2027-03-01next 2027-12-01
SBFM
Shenyang Sunshine Pharmaceutical Co., LTD.distress 3/10 · well-funded / low risk$1.76-3%today-92% from 52w high
Oncology 1
Lead: Advanced Malignant Tumors
Revenue
pre-revenue
Liquidity
$7M
Runway
1.2 yrs
Shares 1y
+10%
Price & events
-85.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-3.8%
1W
-13.7%
1M
-82.2%
3M
-85.7%
6M
-88.9%
1Y
-97.3%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $8.81M
- Volume
- 7.14K
- 52 Week Range
- $1.73 – $22.00
- Total Shares
- 5.01M
- Float Shares
- 497.44K
- Short %
- 5.37%
- % Held by Insiders
- 0.48%
- % Held by Institutions
- 12.87%
- RVOL
- 0.07x
- Beta
- 1.31
Pipeline stages · 6 programs
SSGJ-709
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SPGL008
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SSS59
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SSS06, rhEPO
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
HBT-708
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[14C]SSS17
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 12 trials · 10 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-30 Estimated 50% readout ~2026-10-13 | Phase 3 | SSGJ-707, Pembrolizumab | Advanced Non-Small Cell Lung Cancer | — | recruiting |
| 2026-08-31 Estimated 50% readout ~2026-10-15 | Phase 2 | SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel | First-line Advanced NSCLC Patients | — | recruiting |
| 2026-09-22 Estimated 50% readout ~2026-10-22 | Phase 1 | SPGL008 | Advanced Malignant Tumors | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | SSGJ-706, XELOX, Bevacizumab | Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer | — | not yet recruiting |
| 2026-12-31 Estimated 50% readout ~2027-02-14 | Phase 2 | SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherap | Locally Advanced, Recurrent or Metastatic Malignancies | — | recruiting |
Show all 12 trials · 7 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03-01 Estimated 50% readout ~2027-03-31 | Phase 1 | SSS59 | Malignant Tumors | — | recruiting |
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 2 | SSGJ-705, SSGJ-612, SSGJ-705 combined with chemotherapy | Locally Advanced (Unresectable) or Metastatic Solid Tumors | — | recruiting |
| 2027-09-30 Estimated 50% readout ~2027-10-30 | Phase 1 | SSGJ-709 | Advanced Malignant Tumors | — | recruiting |
| 2027-12-01 Estimated 50% readout ~2028-01-15 | Phase 2 | SSS06, rhEPO | Chemotherapy-induced Anemia, Non-myeloid Malignancies | — | not yet recruiting |
| 2028-11-21 Estimated 50% readout ~2029-01-05 | Phase 1/2 | SPGL008 | NMIBC | — | not yet recruiting |
| 2026-03-01 | Phase 1 | HBT-708 | Advanced Solid Tumors | 60 | recruiting |
| 2025-07 | Phase 1 | [14C]SSS17 | Healthy Subjects (HS) | 6 | not yet recruiting |
Catalyst news & presentations · 1
- 2026-03-06partnershipEngaged Aegis Capital Corp. as warrant solicitation agent on best efforts basis for 3 months.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 5,005,945 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-10-08Aegis CapitalBuy
- 2024-12-05Aegis CapitalBuy
Competitors — Advanced Malignant Tumors
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
Recent news
- 2026-07-22Price to sales forward of Sunshine Biopharma Inc. – NASDAQ:SBFMW - TradingView
- 2026-07-20Sunshine Biopharma plans up to $4 million at-the-market share sale via Aegis Capital - Bitget
- 2026-07-20Sunshine Biopharma (SBFM) Reports Breakthrough Research on SARS-CoV-2 Treatment - GuruFocus
- 2026-07-20Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - The Daily Corinthian
- 2026-07-20Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - Times Argus
- 2026-07-20Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - The Joplin Globe
- 2026-07-20Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - Weatherford Democrat
- 2026-07-20Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - Corsicana Daily Sun
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.